EUVIMEDEUVIMED entdecken
FallberichtOpen Access

The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice

N Y Sviridenko, E V Ananicheva, V M Gershevich, Y O Grusha, K A Chepilev, A V Surov, V V Yurgel, K S Shchukin, E G Bessmertnaya, O A Bilevich

Problems of Endocrinology · 2026

DOI: 10.14341/probl13580 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Problems of Endocrinology, 2026. Verfasst von N Y Sviridenko und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Research Centre. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glucocorticoids, Graves Ophthalmopathy, Optic Nerve Diseases. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid eye disease (TED) is an autoimmune pathology of the orbital tissues associated with autoimmune thyroid disease, most commonly occurring with Graves’ disease. The clinical presentation of TED is extremely diverse, ranging from mild orbital involvement to potentially vision-threatening optical neuropathy. Early diagnosis of the active phase of TED is crucial, as immunosuppressive therapy is effective only during this phase, while treatment for patients in the inactive phase consists only of rehabilitative surgery. High-dose intravenous glucocorticoids are the first-line treatment for patients with moderate to severe active TED. Glucocorticoids are widely used due to their anti-inflammatory and immunosuppressive properties, but about 20–30% of patients remain resistant to glucocorticoid treatment. One promising direction in the treatment of glucocorticoid-resistant TED is the use of monoclonal antibodies targeting specific antigen epitopes. We present a clinical case of tocilizumab treatment in severe glucocorticoid-resistant TED complicated by optic neuropathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGlucocorticoidsGraves OphthalmopathyOptic Nerve DiseasesHumansDrug ResistanceImmunosuppressive AgentsTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedGlucocorticoidsImmunosuppressive Agentstocilizumab

Autor:innen und Institutionen

  • Endocrinology Research Centre.
  • City Clinical Hospital No. 1 Named After A.N. Kabanov; Clinical Ophthalmologic Hospital named after V.P. Vykhodtsev.
  • Omsk State Medical University.
  • Research Institute of Eye Diseases Named After M.M. Krasnov.
  • Clinical Ophthalmologic Hospital named after V.P. Vykhodtsev.
  • Omsk State Medical University; Clinical Ophthalmologic Hospital named after V.P. Vykhodtsev.

Zitieren

APA

Sviridenko, N. Y., Ananicheva, E. V., Gershevich, V. M., Grusha, Y. O., Chepilev, K. A., Surov, A. V., Yurgel, V. V., Shchukin, K. S., Bessmertnaya, E. G., & Bilevich, O. A. (2026). The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice. Problems of Endocrinology. https://doi.org/10.14341/probl13580

Vancouver

Sviridenko NY, Ananicheva EV, Gershevich VM, Grusha YO, Chepilev KA, Surov AV, et al. The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice. Problems of Endocrinology. 2026. doi:10.14341/probl13580

BibTeX
@article{Sviridenko2026,
  author = {Sviridenko, N Y and Ananicheva, E V and Gershevich, V M and Grusha, Y O and Chepilev, K A and Surov, A V and Yurgel, V V and Shchukin, K S and Bessmertnaya, E G and Bilevich, O A},
  title = {The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice},
  journal = {Problems of Endocrinology},
  year = {2026},
  doi = {10.14341/probl13580}
}
Kostenlos starten →